LY-487379

LY-487379 is a selective positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 2 (mGluR2), developed by Eli Lilly for scientific research purposes[2][3][7]. It acts by binding allosterically to the mGluR2 receptor, enhancing the response to endogenous glutamate without intrinsic agonist or antagonist activity, and does not affect mGluR3[1][7]. LY-487379 has demonstrated anxiolytic and procognitive effects in various animal models, notably facilitating cognitive flexibility, behavioral inhibition, and reducing glutamate and other neurotransmitter levels in specific brain regions[2][5]. It has been investigated for its potential therapeutic benefits in schizophrenia, Parkinson’s disease (particularly for levodopa-induced dyskinesia), and cognitive deficit models[2][4][5][8].

Other names

LY-487379LY487379LY 487379N-(4-(2-methoxyphenoxy)-phenyl)-N-(2,2,2-trifluoroethylsulfonyl)-pyrid-3-ylmethylamineLY-487379 hydrochlorideLY487379 hydrochlorideLY 487379 hydrochloride